[go: up one dir, main page]

SI3280447T1 - Farmacevtske formulacije - Google Patents

Farmacevtske formulacije

Info

Publication number
SI3280447T1
SI3280447T1 SI201630246T SI201630246T SI3280447T1 SI 3280447 T1 SI3280447 T1 SI 3280447T1 SI 201630246 T SI201630246 T SI 201630246T SI 201630246 T SI201630246 T SI 201630246T SI 3280447 T1 SI3280447 T1 SI 3280447T1
Authority
SI
Slovenia
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Application number
SI201630246T
Other languages
English (en)
Inventor
Chaitanya Dutt
Jaya Abraham
Vivek Mishra
Amit Kesarwani
Ramesh Chandra Gupta
Shailesh Deshpande
Shital Kumar Zambad
Anoop Mathur
Jignesh Kotecha
Sachin Latad
Manish Patel
Anita Chaudhari
Original Assignee
Torrent Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Limited filed Critical Torrent Pharmaceuticals Limited
Publication of SI3280447T1 publication Critical patent/SI3280447T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201630246T 2015-04-08 2016-04-05 Farmacevtske formulacije SI3280447T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1475MU2015 2015-04-08
PCT/IB2016/051920 WO2016162787A1 (en) 2015-04-08 2016-04-05 Pharmaceutical formulations
EP16718474.6A EP3280447B1 (en) 2015-04-08 2016-04-05 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
SI3280447T1 true SI3280447T1 (sl) 2019-06-28

Family

ID=55808800

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201630246T SI3280447T1 (sl) 2015-04-08 2016-04-05 Farmacevtske formulacije

Country Status (31)

Country Link
US (1) US10772879B2 (sl)
EP (1) EP3280447B1 (sl)
JP (1) JP6736656B2 (sl)
KR (1) KR20170134662A (sl)
CN (1) CN107530287B (sl)
AR (1) AR104185A1 (sl)
AU (1) AU2016246124B2 (sl)
BR (1) BR112017021669A2 (sl)
CA (1) CA2997463A1 (sl)
CY (1) CY1121921T1 (sl)
DK (1) DK3280447T3 (sl)
EA (1) EA037041B1 (sl)
ES (1) ES2724629T3 (sl)
HR (1) HRP20190783T1 (sl)
HU (1) HUE044889T2 (sl)
IL (1) IL254794B (sl)
LT (1) LT3280447T (sl)
MX (1) MX387639B (sl)
MY (1) MY182008A (sl)
PH (1) PH12017501829A1 (sl)
PL (1) PL3280447T3 (sl)
PT (1) PT3280447T (sl)
RS (1) RS58708B1 (sl)
SG (1) SG11201708142XA (sl)
SI (1) SI3280447T1 (sl)
SM (1) SMT201900264T1 (sl)
TR (1) TR201906476T4 (sl)
TW (1) TWI713512B (sl)
UA (1) UA123051C2 (sl)
WO (1) WO2016162787A1 (sl)
ZA (1) ZA201707094B (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3169368A1 (en) 2012-06-15 2014-01-09 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
PL2976072T3 (pl) 2013-03-22 2021-11-22 Nova Southeastern University Drobne cząstki epinefryny i sposoby ich stosowania do leczenia chorób reagujących na epinefrynę
KR20210080429A (ko) 2018-10-19 2021-06-30 노바 사우쓰이스턴 유니버시티 피에이치 조절 부형제 및 침투 향상제를 포함하는 설하 에피네프린 조성물 및 그의 사용 방법
PL3949952T3 (pl) 2019-04-03 2024-10-14 Astellas Pharma Inc. Kompozycja farmaceutyczna
KR102330597B1 (ko) * 2020-04-17 2021-11-26 보령제약 주식회사 무정형의 엠파글리플로진을 포함하는 안정성이 향상된 신규 약제학적 제형
KR20220080880A (ko) * 2020-12-08 2022-06-15 주식회사 종근당 엠파글리플로진 공결정을 함유하는 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301477T3 (es) * 1999-02-22 2008-07-01 Merrion Research I Limited Forma de dosificacion oral solida que contiene un potenciador.
DE69915143T2 (de) 1999-10-06 2004-10-14 Torrent Pharmaceuticals Ltd., Ahmedabad Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen
ATE299496T1 (de) 2001-03-21 2005-07-15 Torrent Pharmaceuticals Ltd Pyridiniumverbindungen zur behandlung von age- relatierten krankheiten
MX2008011227A (es) 2006-03-03 2009-02-10 Torrent Pharmaceuticals Ltd Receptores antagonistas de accion nueva y doble en los receptores at1 y eta.
JP2009023932A (ja) * 2007-07-18 2009-02-05 Tama Tlo Kk N−メチルピリジニウム化合物を有効成分として含有する抗ウイルス剤、それを含有する、抗ウイルス組成物、食餌及び動物用飼料
BRPI0907650A2 (pt) * 2008-01-25 2015-07-21 Torrent Pharmaceuticals Ltd Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc
CN101574343B (zh) * 2008-05-07 2011-06-01 吉林大学 一种治疗糖尿病的药物组合物
EP2427432A2 (en) * 2009-05-07 2012-03-14 Torrent Pharmaceuticals Limited Novel heterocyclic compounds
AU2010339907A1 (en) * 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
CN104069066B (zh) * 2013-03-25 2017-04-19 吉林大学 黄癸固体分散体及其在治疗糖尿病及并发症中的应用

Also Published As

Publication number Publication date
CN107530287A (zh) 2018-01-02
MY182008A (en) 2021-01-18
AU2016246124B2 (en) 2019-11-14
CY1121921T1 (el) 2020-10-14
HRP20190783T1 (hr) 2019-06-28
UA123051C2 (uk) 2021-02-10
KR20170134662A (ko) 2017-12-06
EA201792237A1 (ru) 2018-02-28
TW201642858A (zh) 2016-12-16
MX387639B (es) 2025-03-18
PH12017501829A1 (en) 2018-04-23
EA037041B1 (ru) 2021-01-29
CN107530287B (zh) 2020-11-10
DK3280447T3 (da) 2019-05-13
EP3280447A1 (en) 2018-02-14
IL254794B (en) 2021-05-31
CA2997463A1 (en) 2016-10-13
PT3280447T (pt) 2019-05-14
US10772879B2 (en) 2020-09-15
TWI713512B (zh) 2020-12-21
SG11201708142XA (en) 2017-11-29
LT3280447T (lt) 2019-05-27
JP2018510916A (ja) 2018-04-19
AR104185A1 (es) 2017-07-05
US20180110763A1 (en) 2018-04-26
PL3280447T3 (pl) 2019-07-31
MX2017012942A (es) 2018-01-30
ZA201707094B (en) 2021-04-28
HUE044889T2 (hu) 2019-11-28
SMT201900264T1 (it) 2019-07-11
BR112017021669A2 (pt) 2018-07-10
RS58708B1 (sr) 2019-06-28
JP6736656B2 (ja) 2020-08-05
ES2724629T3 (es) 2019-09-12
AU2016246124A1 (en) 2017-11-02
WO2016162787A1 (en) 2016-10-13
TR201906476T4 (tr) 2019-05-21
IL254794A0 (en) 2017-12-31
EP3280447B1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
IL246978A0 (en) New paracetamol formulations
PT4070787T (pt) Formulações farmacêuticas
ZA201903101B (en) Pharmaceutical formulations
IL256491A (en) Pharmaceutical formulations
GB201608323D0 (en) Pharmaceutical compositions
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL253570A0 (en) Pharmacy composition
IL266537A (en) pharmaceutical preparation
IL262745A (en) Improved preparations containing drugs
IL253177B (en) Pharmacy preparation
GB201521462D0 (en) Pharmaceutical composition
ZA201707094B (en) Pharmaceutical formulations
ZA201807851B (en) Pharmaceutical formulation
IL263040A (en) Pharmaceutical composition comprising eteplirsen
GB201515310D0 (en) Pharmaceutical composition
GB201506755D0 (en) Novel pharmaceutical formulation
IL255510A (en) Pharmaceutical compositions
IL271908A (en) Over-compressed pharmaceutical preparations
GB201520862D0 (en) Pharmaceutical composition
GB201511246D0 (en) Pharmaceutical formulation
GB201417589D0 (en) Pharmaceutical Formulations
PL3424500T3 (pl) Kompozycja farmaceutyczna zawierająca famitynib
GB201610440D0 (en) Pharmaceutical formulations
PT3319596T (pt) Composições farmacêuticas
GB201521456D0 (en) Pharmaceutical composition